文献速递脊柱关节炎

银屑病关节炎临床试验中身体功能量表的区分度系统评价

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2020-06-18

该系统评价检索PubMed与Scopus,纳入31项银屑病关节炎随机对照试验的35篇文章,评估HAQ-DI、HAQ-S、SF-36 PCS与SF-36 PF的临床试验区分度。干预组效应量均高于对照组,HAQ-DI与SF-36 PCS获支持,SF-36 PF与HAQ-S需谨慎,HAQ-S需更多研究。

要点

  • HAQ-DI与SF-36 PCS在低偏倚风险试验中区分度获支持。
  • SF-36 PF与HAQ-S的区分度支持需谨慎,HAQ-S尚需更多研究。
  • 干预组效应量普遍高于对照组,符合预期。

核心结论

  • 在银屑病关节炎随机对照试验中,HAQ-DI与SF-36 PCS的临床试验区分度在低偏倚风险下获支持。
  • SF-36 PF与HAQ-S的临床试验区分度获支持但需谨慎,HAQ-S仍需更多研究。

研究设计与样本

  • 系统评价检索PubMed与Scopus英文文献,纳入银屑病关节炎中生物制剂与靶向合成DMARD的原始随机对照试验。
  • 共纳入31项随机对照试验的35篇文章,采用OMERACT良好方法清单评估质量,计算身体功能患者报告结局量表的效应量并用预设假设评价。

主要发现

  • 干预组效应量高于对照组,符合预期。
  • HAQ-DI干预组与对照组效应量中位数分别为-0.73与-0.24。
  • SF-36 PCS干预组与对照组效应量中位数分别为0.77与0.23。

关键数值与推荐

  • HAQ-DI:干预组效应量中位数-0.73,对照组-0.24。
  • SF-36 PCS:干预组效应量中位数0.77,对照组0.23。
  • 可评估的身体功能患者报告结局量表为HAQ-DI、HAQ-S、SF-36 PCS与SF-36 PF。

临床怎么用

  • 在银屑病关节炎随机对照试验中选择身体功能结局量表时,可优先考虑区分度获支持的HAQ-DI与SF-36 PCS。
  • 使用SF-36 PF与HAQ-S解释身体功能结果时应保持谨慎,HAQ-S相关证据尚不充分。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Physical function (PF) is a core domain to be measured in randomized controlled trials (RCTs) of psoriatic arthritis (PsA), yet the discriminative performance of patient reported outcome measures (PROMs) for PF in RCTs has not been evaluated systematically. In this systematic review, we aimed to evaluate the clinical trial discrimination of PF-PROMs in PsA RCTs. METHODS: We searched PubMed and Scopus databases in English to identify all original RCTs on biological and targeted synthetic disease modifying anti-rheumatic drugs (DMARDs) conducted in PsA. We assessed quality in each article using the OMERACT good method checklist. Effect sizes (ES) for the PF-PROMs were calculated and appraised using a priori hypotheses. Evidence supporting clinical trial discrimination for each PF-PROM was summarized to derive recommendations. RESULTS: 35 articles from 31 RCTs were included. Four PF-PROMs had data for evaluation: HAQ-Disability Index (DI), HAQ-Spondyloarthritis (S), and Short Form 36-item Health Survey Physical Component Summary (SF-36 PCS) and Physical Functioning domain (SF-36 PF). As anticipated, higher ES values were observed for intervention groups than the control groups. Across all studies, for HAQ-DI, the median ES were -0.73 and -0.24 for intervention and control groups, respectively. Whereas for SF-36 PCS, the median ES were 0.77 and 0.23. For intervention and control groups, respectively. CONCLUSION: Clinical trial discrimination was supported for HAQ-DI and SF-36 PCS in PsA with low risk of bias; and for SF-36 PF and HAQ-S with some caution. More studies are required for HAQ-S.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Leung YY, Holland R, Mathew AJ, et al. Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. Semin Arthritis Rheum. 2020. PMID: 32927377. doi:10.1016/j.semarthrit.2020.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。